Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices 29825

44231) announcing an earlier meeting of

the Drugs, Biologics, and Therapeutics

Panel (the Panel) and also describing the

Medicare Coverage Advisory Committee

(MCAC), which provides advice and

recommendations to us about clinical

issues. This notice announces the June

20, 2001 public MCAC meeting of the

Drugs, Biologics, and Therapeutics

Panel.

Current Panel Members

Thomas V. Holohan, M.A., M.D.,

FACP; Leslie P. Francis, JD, Ph.D.;

Judith A. Cahill, M.A.; Michael L.

Friedland, M.D.; Kathy J. Helzlsouer,

M.D., M.H.S.; Robert C. Johnson, M.S.;

Ronald P. Jordan, R.Ph.; Mitchell

Sugarman, M.B.A., M.S.; Cathleen M.

Dooley, M.A.; Christine M. Grant, JD.

Meeting Topic

The Panel will hear and discuss

presentations from interested persons

regarding the use of levo-carnitine in

end stage renal disease patients.

Procedure and Agenda

This meeting is open to the public.

The Panel will hear oral presentations

from the public for approximately 2.5

hours. The Panel may limit the number

and duration of oral presentations to the

time available. If you wish to make

formal presentations you must notify

the Executive Secretary named in the

FOR FURTHER INFORMATION CONTACT

section of this notice. In addition, you

must submit the following by the

Deadline for Presentations and

Comments date listed in the DATES

section of this notice: a brief statement

of the general nature of the evidence or

arguments you wish to present and the

names and addresses of proposed

participants; and a written copy of your

presentation to the Executive Secretary

before the meeting. We will request that

you declare at the meeting whether or

not you have any financial involvement

with manufacturers of any items or

services being discussed (or with their

competitors).

After the public and our

presentations, the Panel will deliberate

openly on the topic. Interested persons

may observe the deliberations, but the

Panel will not hear further comments

during this time except at the request of

the chairperson. The Panel will also

allow approximately a 30-minute open

public session for any attendee to

address issues specific to the topic. At

the conclusion of the day, the members

will vote and the Panel will make its

recommendation.

Authority: 5 U.S.C. App. 2, section 10(a)(1)

and (a)(2).

(Catalog of Federal Domestic Assistance

Program No. 93.774, Medicare—

Supplementary Medical Insurance Program)

Dated: May 25, 2001.

Jeffrey L. Kang, M.D.,

Director, Office of Clinical Standards and

Quality, Health Care Financing

Administration.

[FR Doc. 01–13846 Filed 5–31–01; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be listed at the end, and will be omitted

from the monthly listing thereafter.

This Notice is also available on the

internet at the following website:

http://www.health.org/workplace.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh or Dr. Walter Vogl,

Division of Workplace Programs, 5600

Fishers Lane, Rockwall 2 Building,

Room 815, Rockville, Maryland 20857;

Tel.: (301) 443–6014, Fax: (301) 443–

3031.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection.

To maintain that certification a

laboratory must participate in a

quarterly performance testing program

plus periodic, on-site inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACL Laboratories, 8901 W. Lincoln

Ave., West Allis, WI 53227, 414–328–

7840/800–877–7016 (Formerly:

Bayshore Clinical Laboratory)

Advanced Toxicology Network, 3560

Air Center Cove, Suite 101, Memphis,

TN 38118, 901–794–5770/888–290–

1150

Aegis Analytical Laboratories, Inc., 345

Hill Ave., Nashville, TN 37210, 615–

255–2400

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931 / 334–263–5745

Alliance Laboratory Services, 3200

Burnet Ave., Cincinnati, OH 45229,

513–585–9000 (Formerly: Jewish

Hospital of Cincinnati, Inc.)

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

20151, 703–802–6900

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866 / 800–433–2750

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–202–2783

(Formerly: Forensic Toxicology

Laboratory Baptist Medical Center) ]

Clinical Laboratory Partners, LLC, 129

East Cedar St., Newington, CT 06111,

860–696–8115 (Formerly: Hartford

Hospital Toxicology Laboratory)

Clinical Reference Lab, 8433 Quivira

Rd., Lenexa, KS 66215–2802 800–

445–6917

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652 / 417–269–3093 (Formerly:

Cox Medical Centers)

Dept. of the Navy, Drug Screening

Laboratory, Great Lakes, IL, Building

38–H, P. O. Box 88–6819, Great Lakes,

29826 Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices

IL 60088–6819, 847–688–2045 / 847–

688–4171

Diagnostic Services Inc., dba DSI, 12700

Westlinks Drive, Fort Myers, FL

33913, 941–561–8200 / 800–735–5416

Doctors Laboratory, Inc., PO. Box 2658,

2906 Julia Dr., Valdosta, GA 31602,

912–244–4468

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104

206–386–2672 / 800–898–0180

(Formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of

Laboratory of Pathology of Seattle,

Inc.)

DrugScan, Inc., P.O. Box 2969, 1119

Mearns Rd., Warminster, PA 18974,

215–674–9310

Dynacare Kasper Medical Laboratories,*

14940–123 Ave., Edmonton, Alberta,

Canada T5V1B4, 780–451–3702/800–

661–9876

ElSohly Laboratories, Inc., 5 Industrial

Park Dr., Oxford, MS 38655, 662–236–

2609

Express Analytical Labs, 1301 18th Ave.

NW., Suite 110, Austin, MN 55912,

507–437–7322

Gamma-Dynacare Medical

Laboratories,* A Division of the

Gamma-Dynacare Laboratory

Partnership, 245 Pall Mall St.,

London, ONT, Canada N6A 1P4, 519–

679–1630

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715, 608–

267–6267

Integrated Regional Laboratories, 5361

NW 33rd Avenue, Fort Lauderdale, FL

33309, 954–777–0018, 800–522–0232

(Formerly: Cedars Medical Center,

Department of Pathology)

Kroll Laboratory Specialists, Inc., 1111

Newton St., Gretna, LA 70053, 504–

361–8989/800–433–3823 (Formerly:

Laboratory Specialists, Inc.)

LabOne, Inc., 10101 Renner Blvd.,

Lenexa, KS 66219, 913–888–3927/

800–728–4064 (Formerly: Center for

Laboratory Services, a Division of

LabOne, Inc.)

Laboratory Corporation of America

Holdings, 7207 N. Gessner Road,

Houston, TX 77040, 713–856–8288/

800–800–2387

Laboratory Corporation of America

Holdings, 69 First Ave., Raritan, NJ

08869, 908–526–2400/800–437–4986

(Formerly: Roche Biomedical

Laboratories, Inc.)

Laboratory Corporation of America

Holdings, 1904 Alexander Drive,

Research Triangle Park, NC 27709,

919–572–6900/800–833–3984

(Formerly: LabCorp Occupational

Testing Services, Inc., CompuChem

Laboratories, Inc.;

CompuChemLaboratories, Inc., A

Subsidiary of Roche Biomedical

Laboratory; Roche CompuChem

Laboratories, Inc., A Member of the

Roche Group)

Laboratory Corporation of America

Holdings, 1120 Stateline Road West,

Southaven, MS 38671, 866–827–8042/

800–233–6339 (Formerly: LabCorp

Occupational Testing Services, Inc.,

MedExpress/National Laboratory

Center)

Marshfield Laboratories, Forensic

Toxicology Laboratory, 1000 North

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–331–3734

MAXXAM Analytics Inc.*, 5540

McAdam Rd., Mississauga, ON,

Canada L4Z 1P1, 905–890–2555

(Formerly: NOVAMANN (Ontario)

Inc.)

Medical College Hospitals Toxicology

Laboratory, Department of Pathology,

3000 Arlington Ave., Toledo, OH

43699, 419–383–5213

MedTox Laboratories, Inc., 402 W.

County Rd. D, St. Paul, MN 55112,

651–636–7466/800–832–3244

MetroLab-Legacy Laboratory Services,

1225 NE 2nd Ave., Portland, OR

97232, 503–413–5295/800–950–5295

Minneapolis Veterans Affairs Medical

Center, Forensic Toxicology

Laboratory, 1 Veterans Drive,

Minneapolis, Minnesota 55417, 612–

725–2088

National Toxicology Laboratories, Inc.,

1100 California Ave., Bakersfield, CA

93304, 661–322–4250/800–350–3515

Northwest Drug Testing, a division of

NWT Inc., 1141 E. 3900 South, Salt

Lake City, UT 84124, 801–293–2300/

800–322–3361, (Formerly: NWT Drug

Testing, NorthWest Toxicology, Inc.)

One Source Toxicology Laboratory, Inc.,

1705 Center Street, Deer Park, TX

77536, 713–920–2559 (Formerly:

University of Texas Medical Branch,

Clinical Chemistry Division; UTMB

Pathology-Toxicology Laboratory)

Oregon Medical Laboratories, P.O. Box

972, 722 East 11th Ave., Eugene, OR

97440–0972, 541–687–2134

Pacific Toxicology Laboratories, 6160

Variel Ave., Woodland Hills, CA

91367, 818–598–3110/800–328–6942

(Formerly: Centinela Hospital Airport

Toxicology Laboratory)

Pathology Associates Medical

Laboratories, 11604 E. Indiana Ave.,

Spokane, WA 99206, 509–926–2400/

800–541–7891

PharmChem Laboratories, Inc., Texas

Division, 7606 Pebble Dr., Fort Worth,

TX 76118, 817–215–8800 (Formerly:

Harris Medical Laboratory)

Physicians Reference Laboratory, 7800

West 110th St., Overland Park, KS

66210, 913–339–0372/800–821–3627

Poisonlab, Inc., 7272 Clairemont Mesa

Blvd., San Diego, CA 92111, 858–279–

2600/800–882–7272

Quest Diagnostics Incorporated, 3175

Presidential Dr., Atlanta, GA 30340,

770–452–1590 (Formerly: SmithKline

Beecham Clinical Laboratories,

SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated, 4444

Giddings Road, Auburn Hills, MI

48326, 248–373–9120/800–444–0106

(Formerly: HealthCare/Preferred

Laboratories, HealthCare/MetPath,

CORNING Clinical Laboratories)

Quest Diagnostics Incorporated, 4770

Regent Blvd., Irving, TX 75063, 800–

842–6152 (Moved from the Dallas

location on 03/31/01; Formerly:

SmithKline Beecham Clinical

Laboratories, SmithKline Bio-Science

Laboratories)

Quest Diagnostics Incorporated, 801

East Dixie Ave., Suite 105A, Leesburg,

FL 34748, 352–787–9006x4343

(Formerly: SmithKline Beecham

Clinical Laboratories, Doctors &

Physicians Laboratory)

Quest Diagnostics Incorporated, 400

Egypt Rd., Norristown, PA 19403,

610–631–4600/800–877–7484

(Formerly: SmithKline Beecham

Clinical Laboratories, SmithKline BioScience Laboratories)

Quest Diagnostics Incorporated, 506 E.

State Pkwy., Schaumburg, IL 60173,

800–669–6995/847–885–2010

(Formerly: SmithKline Beecham

Clinical Laboratories, International

Toxicology Laboratories)

Quest Diagnostics Incorporated, 7470

Mission Valley Rd., San Diego, CA

92108–4406, 619–686–3200/800–446–

4728 (Formerly: Nichols Institute,

Nichols Institute Substance Abuse

Testing (NISAT), CORNING Nichols

Institute, CORNING Clinical

Laboratories)

Quest Diagnostics Incorporated, One

Malcolm Ave., Teterboro, NJ 07608,

201–393–5590 (Formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories, CORNING Clinical

Laboratory)

Quest Diagnostics Incorporated, 7600

Tyrone Ave., Van Nuys, CA 91405,

818–989–2520 / 800–877–2520

(Formerly: SmithKline Beecham

Clinical Laboratories)

Scientific Testing Laboratories, Inc., 463

Southlake Blvd., Richmond, VA

23236, 804–378–9130

S.E.D. Medical Laboratories, 5601 Office

Blvd., Albuquerque, NM 87109, 505–

727–6300/800–999–5227

South Bend Medical Foundation, Inc.,

530 N. Lafayette Blvd., South Bend,

IN 46601, 219–234–4176

Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices 29827

Southwest Laboratories, 2727 W.

Baseline Rd., Tempe, AZ 85283, 602–

438–8507/800–279–0027

Sparrow Health System, Toxicology

Testing Center, St. Lawrence Campus,

1210 W. Saginaw, Lansing, MI 48915,

517–377–0520 (Formerly: St.

Lawrence Hospital & Healthcare

System)

St. Anthony Hospital Toxicology

Laboratory, 1000 N. Lee St.,

Oklahoma City, OK 73101, 405–272–

7052

Toxicology & Drug Monitoring

Laboratory, University of Missouri

Hospital & Clinics, 2703 Clark Lane,

Suite B, Lower Level, Columbia, MO

65202, 573–882–1273

Toxicology Testing Service, Inc., 5426

N.W. 79th Ave., Miami, FL 33166,

305–593–2260

Universal Toxicology Laboratories, LLC,

9930 W. Highway 80, Midland, TX

79706, 915–561–8851/888–953–8851

The following laboratory voluntarily

withdrew from the National Laboratory

Certification Program on May 31, 2001:

PharmChem Laboratories, Inc., 1505–A

O’Brien Dr., Menlo Park, CA 94025

650–328–6200/800–446–5177

* The Standards Council of Canada

(SCC) voted to end its Laboratory

Accreditation Program for Substance

Abuse (LAPSA) effective May 12, 1998.

Laboratories certified through that

program were accredited to conduct

forensic urine drug testing as required

by U.S. Department of Transportation

(DOT) regulations. As of that date, the

certification of those accredited

Canadian laboratories will continue

under DOT authority. The responsibility

for conducting quarterly performance

testing plus periodic on-site inspections

of those LAPSA-accredited laboratories

was transferred to the U.S. DHHS, with

the DHHS’ National Laboratory

Certification Program (NLCP) contractor

continuing to have an active role in the

performance testing and laboratory

inspection processes. Other Canadian

laboratories wishing to be considered

for the NLCP may apply directly to the

NLCP contractor just as U.S. laboratories

do.

Upon finding a Canadian laboratory to

be qualified, the DHHS will recommend

that DOT certify the laboratory (Federal

Register, 16 July 1996) as meeting the

minimum standards of the ‘‘Mandatory

Guidelines for Workplace Drug Testing’’

(59 Federal Register, 9 June 1994, Pages

29908–29931). After receiving the DOT

certification, the laboratory will be

included in the monthly list of DHHS

certified laboratories and participate in

the NLCP certification maintenance

program.

Richard Kopanda,

Executive Officer, Substance Abuse and

Mental Health Services Administration.

[FR Doc. 01–13733 Filed 5–31–01; 8:45 am]

BILLING CODE 4160–20–P

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–4650–N–39]

Notice of Submission of Proposed

Information Collection to OMB;

Minimum Property Standards for

Housing

AGENCY: Office of the Chief Information

Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information

collection requirement described below

has been submitted to the Office of

Management and Budget (OMB) for

review, as required by the Paperwork

Reduction Act. The Department is

soliciting public comments on the

subject proposal.

DATES: Comments Due Date: July 2,

2001.

ADDRESSES: Interested persons are

invited to submit comments regarding

this proposal. Comments should refer to

the proposal by name and/or OMB

approval number (2502–0321) and

should be sent to: Joseph F. Lackey, Jr.,

OMB Desk Officer, Office of

Management and Budget, Room 10235,

New Executive Office Building,

Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT:

Wayne Eddins, Reports Management

Officer, Q, Department of Housing and

Urban Development, 451 Seventh Street,

SW., Washington, DC 20410; e-mail

Wayne_Eddins@HUD.gov; telephone

(202) 708–2374. This is not a toll-free

number. Copies of the proposed forms

and other available documents

submitted to OMB may be obtained

from Mr. Eddins.

SUPPLEMENTARY INFORMATION: The

Department has submitted the proposal

for the collection of information, as

described below, to OMB for review, as

required by the Paperwork Reduction

Act (44 U.S.C. Chapter 35). The Notice

lists the following information: (1) The

title of the information collection

proposal; (2) the office of the agency to

collect the information; (3) the OMB

approval number, if applicable; (4) the

description of the need for the

information and its proposed use; (5)

the agency form number, if applicable;

(6) what members of the public will be

affected by the proposal; (7) how

frequently information submissions will

be required; (8) an estimate of the total

number of hours needed to prepare the

information submission including

number of respondents, frequency of

response, and hours of response; (9)

whether the proposal is new, an

extension, reinstatement, or revision of

an information collection requirement;

and (10) the name and telephone

number of an agency official familiar

with the proposal and of the OMB Desk

Officer for the Department.

This Notice also lists the following

information:

Title of Proposal: Minimum Property

Standards for Housing.

OMB Approval Number: 2502–0321.

Form Numbers: None.

Description of the Need for the

Information and Its Proposed Use:

Information on local property standards

for assisted multifamily housing and

care-type facilities is collected from

State and local governments to assess

the equivalency of their existing

housing standards in meeting HUD’s

minimum requirements. If such State or

local codes are deemed equivalent, HUD

assisted properties need only comply

with such equivalent codes.

Respondents: State, Local or Tribal

Government.

Frequency of Submission: On

occasion.

Reporting Burden Number of respondents × Frequency of

response × Hours per response = Burdenhours

1,350 1 8 10,800